Pharmaceuticals, Biotechnology and Life Sciences
– Positive interim analysis data from the TOPAZ Phase 2 trial demonstrated proof-of-concept for apitegromab (SRK-015) in patients with Type…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced two presentations highlighting…
– Presentations Demonstrate Ability of Seagen Antibody-Drug Conjugates to Elicit Immunogenic Cell Death Effect Across Multiple Tumor Types – –…
EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, announced…
Regulatory submissions based on positive data from Phase III FIDELIO-DKD study recently published in the New England Journal of Medicine…
Underscores importance of serological testing using the S1 subunit for worldwide seroprevalence and vaccine development WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE:…
⎯ Trial-in-progress update on the Phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to TLR8 agonist, in subjects…
PALO ALTO, Calif.–(BUSINESS WIRE)–#cancer–Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company, will present preclinical data evaluating IO-108, a novel…
Top-line Results from UGN-102 OPTIMA II Phase 2b Trial Expected by Year End 2020; On Track to Initiate Phase 3…
CAMBRIDGE, Mass. & HAIFA, Israel–(BUSINESS WIRE)–#creditsuisse–Minovia Therapeutics, a clinical-stage company focused on the development of cell-based Mitochondrial Augmentation Therapy (MAT)…